Skip to main content
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
letter
. 2008 Feb 13;46(4):1566–1567. doi: 10.1128/JCM.02299-07

Prevalence of Fecal Carriage of Acquired Expanded-Spectrum Cephalosporin Resistance in Enterobacteriaceae Strains from Cattle in France

Jean-Yves Madec 1,*, Corinne Lazizzera 1, Pierre Châtre 1, Danièle Meunier 1, Sylvie Martin 1, Gérard Lepage 1, Marie-Françoise Ménard 1, Patricia Lebreton 1, Thomas Rambaud 1
PMCID: PMC2292943  PMID: 18272707

In gram-negative pathogens, extended-spectrum beta-lactamases (ESBLs) confer resistance to penicillins, cephalosporins (including extended-spectrum cephalosporins), and aztreonam, but not to cephamycins and carbapenems, and are inhibited by beta-lactamase inhibitors (8). Recently, cefotaximases have become the most prevalent ESBLs worldwide (7) and have also been detected in animals (see, for instance, references 2 and 9).

Contrary to the human field (see, for instance, references 10, 11, and 13), little has been reported on the prevalence of fecal carriage of ESBL producers by animals (1, 3, 4, 12), and this issue was examined here by testing 1,264 nonduplicate specimens collected from cattle at farms and slaughterhouses in France.

From March to October 2006, fecal samples from 657 sick cattle (farm) were plated on agar supplemented with ceftazidime (1 μg/ml) or cefotaxime (1 μg/ml), 117 of which allowed colonies to grow. After determination of MICs with ESBL Etest strips, 52 ESBL or cephalosporinase producers were identified. Species identification revealed 41 Escherichia coli and 11 non-E. coli isolates, i.e., 7 of Acinetobacter sp., 2 of Pseudomonas aeruginosa, 1 of Citrobacter freundii, and 1 of Hafnia alvei. Antibiotic susceptibility testing, including a double-disk synergy test, confirmed an acquired bla-encoded phenotype in all of the E. coli isolates, whereas a natural phenotype was identified in all 11 non-E. coli isolates. The 41 E. coli isolates were tested by PCR for the blaTEM, blaSHV, blaOXA, blaCMY, and blaCTX-M groups as described previously (9), revealing 17 ESBL producers (12 blaCTX-M-1 isolates, 1 blaCTX-M-15 isolate, 3 blaCTX-M-14 isolates, and 1 blaTEM-126 isolate), either alone (15 isolates) or with a blaTEM gene (2 isolates).

Similarly, of the fecal samples collected from 607 healthy cattle at abattoirs from March 2005 to June 2006, 61 allowed colonies to grow, 46 of which were ESBL or cephalosporinase producers (35 E. coli and 11 non-E. coli isolates, i.e., 8 Acinetobacter sp. isolates, 1 Pseudomonas aeruginosa isolate, 1 Enterobacter cloacae isolate, and 1 Hafnia alvei isolate). Only the 35 E. coli isolates harbored an acquired bla-encoded phenotype, 25 of which produced ESBLs (21 had blaCTX-M-1, 2 had blaCTX-M-14, and 2 had blaSHV-12), either alone (19 isolates) or with a blaTEM gene (6 isolates).

Thus, the prevalence of E. coli producing acquired expanded-spectrum cephalosporinases was 6.2% and 5.8% in sick and healthy cattle, respectively (Table 1). All 42 ESBL-producing E. coli isolates were qnrA, -B, and -S negative by PCR, and most of them (39/42) showed unrelated pulsed-field gel electrophoresis patterns (not shown).

TABLE 1.

Cephalosporin resistance in E. coli isolates from sick and healthy cattle

Cattle group (no.) and cephalosporin resistance mechanism No. of E. coli isolates % in cattle
Sick (657)
    CTX-M alone 14 2.1
    CTX-M + TEM 2 0.3
    Other ESBL alone 1 0.2
    All ESBLs 17 2.6
    CMY 2 0.3
    Non-CMYa 22 3.4
    All non-ESBLs 24 3.7
    All acquired cephalosporin resistance mechanisms 41 6.2
Healthy (607)
    CTX-M alone 17 2.8
    CTX-M + TEM 6 1.0
    Other ESBL alone 2 0.3
    All ESBLs 25 4.1
    Non-CMYa 10 1.6
    All non-ESBLs 10 1.6
    All acquired cephalosporin resistance mechanisms 35 5.8
a

Another chromosomal or plasmidic AmpC mechanism, as deduced from resistance to cefoxitin, cefotaxime, and ceftazidime, but not cefepime, cefpirome, and imipenem, and without cephalosporin-clavulanate synergy.

The use of expanded-spectrum cephalosporins (such as ceftiofur) in veterinary medicine may select ESBL producers in animals. Most genes were of the CTX-M-1 group, so that the epidemiology in farm animals seems to mirror the trend observed in humans in France (5, 6). The absence of the qnr gene was reassuring, and the predominant absence of clonality may argue for multiple transferable genetic elements supporting ESBL-encoding genes.

Overall, our study indicates a worrisome prevalence of fecal carriage of cephalosporin resistance in cattle in France, with a higher prevalence of ESBL-producing E. coli at slaughterhouses compared to farms (Table 1).

Acknowledgments

This study was supported in part by a grant from the Direction Générale de l'Alimentation, Ministère de l'Agriculture, France.  We gratefully thank Vincent Jarlier and Jérôme Robert (Hôpital de la Pitié-Salpétrière, Paris, France) for helpful discussions and critical reading of the manuscript.

Footnotes

Published ahead of print on 13 February 2008.

REFERENCES

  • 1.Briñas, L., M. A. Moreno, T. Teshager, Y. Sáenz, M. C. Porrero, L. Domínguez, and C. Torres. 2005. Monitoring and characterization of extended-spectrum β-lactamases in Escherichia coli strains from healthy and sick animals in Spain in 2003. Antimicrob. Agents Chemother. 491262-1264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Carattoli, A., S. Lovari, A. Franco, G. Cordaro, P. Di Matteo, and A. Battisti. 2005. Extended-spectrum β-lactamases in Escherichia coli isolated from dogs and cats in Rome, Italy, from 2001 to 2003. Antimicrob. Agents Chemother. 49833-835. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Costa, D., P. Poeta, Y. Saenz, L. Vinue, B. Rojo-Bezares, A. Jouini, M. Zarazaga, J. Rodrigues, and C. Torres. 2006. Detection of Escherichia coli harbouring extended-spectrum beta-lactamases of the CTX-M, TEM and SHV classes in faecal samples of wild animals in Portugal. J. Antimicrob. Chemother. 581311-1312. [DOI] [PubMed] [Google Scholar]
  • 4.Duan, R. S., T. H. Sit, S. S. Wong, R. C. Wong, K. H. Chow, G. C. Mak, W. C. Yam, L. T. Ng, K. Y. Yuen, and P. L. Ho. 2006. Escherichia coli producing CTX-M beta-lactamases in food animals in Hong Kong. Microb. Drug Resist. 12145-148. [DOI] [PubMed] [Google Scholar]
  • 5.Eckert, C., V. Gautier, M. Saladin-Allard, N. Hidri, C. Verdet, Z. Ould-Hocine, G. Barnaud, F. Delisle, A. Rossier, T. Lambert, A. Philippon, and G.Arlet. 2004. Dissemination of CTX-M-type β-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob. Agents Chemother. 481249-1255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Lartigue, M. F., N. Fortineau, and P. Nordmann. 2005. Spread of novel expanded-spectrum beta-lactamases in Enterobacteriaceae in a university hospital in the Paris area, France. Clin. Microbiol. Infect. 11588-591. [DOI] [PubMed] [Google Scholar]
  • 7.Livermore, D. M., R. Canton, M. Gniadkowski, P. Nordmann, G. M. Rossolini, G. Arlet, J. Ayala, T. M. Coque, I. Kern-Zdanowicz, F. Luzzaro, L. Poirel, and N. Woodford. 2007. CTX-M: changing the face of ESBLs in Europe. J. Antimicrob. Chemother. 59165-174. [DOI] [PubMed] [Google Scholar]
  • 8.Livermore, D. M., and N. Woodford. 2006. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 14413-420. [DOI] [PubMed] [Google Scholar]
  • 9.Meunier, D., E. Jouy, C. Lazizzera, M. Kobisch, and J.-Y. Madec. 2006. CTX-M-1- and CTX-M-15-type β-lactamases in clinical Escherichia coli iso-lates recovered from food-producing animals in France. Int. J. Antimicrob. Agents 28402-407. [DOI] [PubMed] [Google Scholar]
  • 10.Miró, E., B. Mirelis, F. Navarro, A. Rivera, R. J. Mesa, M. C. Roig, L. Gómez, and P. Coll. 2005. Surveillance of extended-spectrum β-lactamases from clinical samples and faecal carriers in Barcelona, Spain. J. Antimicrob. Chemother. 561152-1155. [DOI] [PubMed] [Google Scholar]
  • 11.Potz, N. A. C., R. Hope, M. Warner, A. P. Johnson, and D. M. Livermore on behalf of the London & South East ESBL Project Group. 2006. Prevalence and mechanisms of cephalosporin resistance in Enterobacteriaceae in London and South-East England. J. Antimicrob. Chemother. 58320-326. [DOI] [PubMed] [Google Scholar]
  • 12.Shiraki, Y., N. Shibata, Y. Doi, and Y. Arakawa. 2004. Escherichia coli producing CTX-M-2 β-lactamase in cattle, Japan. Emerg. Infect. Dis. 1069-75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Valverde, A., T. M. Coque, M. P. Sánchez-Moreno, A. Rollán, F. Baquero, and R. Cantón. 2004. Dramatic increase in prevalence of fecal carriage of extended-spectrum β-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J. Clin. Microbiol. 424769-4775. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES